2024-05-01 11:30:13 ET
More on Regeneron Pharmaceuticals
- Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
- Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference (Transcript)
- Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
- Regeneron to 'vigorously defend' against DOJ on Eylea pricing complaint
Read the full article on Seeking Alpha
For further details see:
Regeneron Pharmaceuticals Q1 2024 Earnings Preview